News · 26 weeks380%
2026-04-192026-10-11
Mix2490d
- Insider14(58%)
- Other8(33%)
- SEC Filings1(4%)
- Leadership1(4%)
Latest news
25 items- PRAnixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus ConferenceDr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conferenceSAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference. The conference, hosted by Mayo Clinic and University of Minnesota, will be held November 2–3, 2026, in Rochester, Minnesota.Dr. Conejo-Garcia's presentation is titled "Closing in: Cracking Ovarian Cancer's Resistance t
- PRAnixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialFirst patient in current dose cohort exhibited no progression of her cancer three months aftertreatmentMultiple patients have survived more than one year, including one beyond two yearsNo dose-limiting toxicities observed to dateSAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment. This represents the first such response in Anixa's CAR-T cell thera
- PRAnixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialMultiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to DatePatients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following LymphodepletionSAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Cent
- INSIDERPresident, COO, & CFO Catelani Michael bought $15,620 worth of shares (5,500 units at $2.84), increasing direct ownership by 12% to 50,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $19,460 worth of shares (7,000 units at $2.78), increasing direct ownership by 1% to 672,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Baskies Arnold M bought $13,800 worth of shares (5,000 units at $2.76), increasing direct ownership by 4% to 140,572 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Titterton Lewis H Jr bought $131,907 worth of shares (49,036 units at $2.69), increasing direct ownership by 5% to 1,046,003 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- PRAnixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual property coverage in markets with increasing breast cancer incidence ratesSAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the Company's no
- PRAnixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory BoardSAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board. "Dr. Guerra has been influential in equitable access to cancer screening and clinical trials, and we are excited to have her join our Cancer Business Advisory Board. We look forward to her input and guidance as we advance our breast cancer vaccine to a Phase 2 clinical trial and continue progressing our ongoing ovarian cancer CA
- INSIDERChief Executive Officer Kumar Amit bought $8,250 worth of shares (3,000 units at $2.75), increasing direct ownership by 0.45% to 665,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Titterton Lewis H Jr bought $27,300 worth of shares (10,000 units at $2.73), increasing direct ownership by 1% to 996,967 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $13,800 worth of shares (5,000 units at $2.76), increasing direct ownership by 0.76% to 662,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- SECSEC Form 10-Q filed by Anixa Biosciences Inc.10-Q - Anixa Biosciences Inc (0000715446) (Filer)
- PRAnixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TVSAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S. During the interview, Dr. Kumar will discuss recently announced successes in cancer vaccine development and Anixa's br
- PRAnixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer CenterSAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. Anixa's presentation will be held at 3:40 PM PT with a breakout session to follow. Dr. Kum
- PRAnixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T TherapyBreast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoingOvarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 monthsPresentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer CenterSAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of ca
- PRAnixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceOvarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 monthsBreast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoingPresentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland ClinicSAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of can
- INSIDERChief Executive Officer Kumar Amit bought $17,350 worth of shares (5,000 units at $3.47), increasing direct ownership by 0.77% to 657,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Baskies Arnold M exercised 6,000 shares at a strike of $3.13 and covered exercise/tax liability with 5,428 shares, increasing direct ownership by 0.42% to 135,572 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $17,200 worth of shares (5,000 units at $3.44), increasing direct ownership by 0.77% to 652,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $10,744 worth of shares (3,188 units at $3.37), increasing direct ownership by 0.50% to 647,000 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $11,190 worth of shares (3,000 units at $3.73), increasing direct ownership by 0.47% to 643,812 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERChief Executive Officer Kumar Amit bought $17,300 worth of shares (5,000 units at $3.46), increasing direct ownership by 0.79% to 640,812 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Titterton Lewis H Jr bought $41,640 worth of shares (12,000 units at $3.47), increasing direct ownership by 1% to 986,967 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
- INSIDERDirector Titterton Lewis H Jr bought $9,174 worth of shares (2,797 units at $3.28), increasing direct ownership by 0.29% to 974,967 units (SEC Form 4)4 - Anixa Biosciences Inc (0000715446) (Issuer)
ANIX FAQ
6 questionsWhat does Anixa Biosciences Inc. do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine...Where does ANIX stock trade?
Anixa Biosciences Inc. (ANIX) is listed on NASDAQ.What sector and industry is ANIX in?
Anixa Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ANIX?
Anixa Biosciences Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1000.00 price target on 2025-03-21. Recent price targets range from $800.00 to $1000.00.What companies are similar to ANIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANIX side-by-side with any of them on Quantisnow.How can I track ANIX on Quantisnow?
Quantisnow aggregates Anixa Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANIX to receive live email and push alerts on every new disclosure.